Stereotactic body radiation therapy (SBRT) is both safe and effective for men with low- and intermediate-risk prostate cancer, according to research presented Oct. 22 at the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting.

Women with early-stage breast cancer who receive large doses of radiation once a week for five weeks will experience the same long-term side effects as women who undergo conventional radiation therapy, according to a ten-year study presented Oct. 21 at the 2018 American Society for Radiation Oncology (ASTRO) annual meeting in San Antonio, Texas.

New Big Bore RT and Ingenia Ambition/Elition MR-RT imaging systems and Pinnacle Evolution treatment planning software support improved patient care, accelerated time to treatment and enhanced patient satisfaction.

Stereotactic radiation therapy is a safe and effective treatment for cancer patients with only one kidney, according to research presented at the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting in San Antonio, Texas.

Contrary to recent data suggesting African-Americans face a higher mortality risk from prostate cancer than Caucasian men, a new study presented at the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting suggests African-American men may have higher cure rates when treated with radiation therapy than Caucasian men.

World's first 85cm 64 and 128 slice wide bore CT unit for oncology

A $1.6 million, four-year grant from the National Cancer Institute of the National Institutes of Health (NIH) was awarded to a researcher from Tulane University in Louisiana to develop a prostate cancer scanner that can check whether all traces of cancer have been removed after surgery, according to The Associated Press.

Results of a new randomized, phase II clinical trial have demonstrated an aggressive form of precision radiation therapy can increase the lifespan of oligometastatic cancer patients and doubles how long they can live without cancer, according to the American Society for Radiation Oncology (ASTRO).